Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
DitchCarbon Score
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals's score of 72 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hikma Pharmaceuticals's reported carbon emissions
In 2024, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 120,273,000 kg CO2e for Scope 1 and 2 combined, with Scope 1 emissions at about 38,469,000 kg CO2e and Scope 2 emissions at approximately 85,682,000 kg CO2e (market-based). The company also disclosed Scope 3 emissions of around 42,606,000 kg CO2e, which includes significant contributions from purchased goods and services (approximately 681,235,000 kg CO2e) and use of sold products (about 42,089,000 kg CO2e). Hikma has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment reflects their ongoing efforts to enhance sustainability and reduce their carbon footprint. Notably, since 2017, the company has achieved a 4% reduction in reported GHG emissions from direct fuel usage and electricity consumption. The company aims to achieve net zero emissions by 2050, demonstrating a long-term commitment to climate action. These targets and achievements are part of Hikma's broader strategy to address climate change and contribute to a sustainable future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 16,817,000 | - | - | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
